MX2017013170A - Formulaciones de fenilacetato de l-ornitina. - Google Patents
Formulaciones de fenilacetato de l-ornitina.Info
- Publication number
- MX2017013170A MX2017013170A MX2017013170A MX2017013170A MX2017013170A MX 2017013170 A MX2017013170 A MX 2017013170A MX 2017013170 A MX2017013170 A MX 2017013170A MX 2017013170 A MX2017013170 A MX 2017013170A MX 2017013170 A MX2017013170 A MX 2017013170A
- Authority
- MX
- Mexico
- Prior art keywords
- ornithine phenylacetate
- liver
- patients
- oral formulations
- formulations
- Prior art date
Links
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 208000007788 Acute Liver Failure Diseases 0.000 abstract 1
- 206010000804 Acute hepatic failure Diseases 0.000 abstract 1
- 206010020575 Hyperammonaemia Diseases 0.000 abstract 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 231100000836 acute liver failure Toxicity 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000007386 hepatic encephalopathy Diseases 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000007232 portal hypertension Diseases 0.000 abstract 1
- 208000030954 urea cycle disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Algunas modalidades de la presente solicitud se refieren a formulaciones orales de fenilacetato de L-ornitina y a métodos para preparar las mismas. Estas formulaciones orales ofrecen una ruta alternativa de administración diferente de la administración intravenosa estándar de fenilacetato de L-ornitina para tratar hiperamonemia en pacientes que tiene varias enfermedades y trastornos hepáticos crónicos y agudos, por ejemplo, falla hepática aguda, cirrosis hepática, descompensación hepática, hipertensión portal, encefalopatía hepática, o pacientes con trastornos del ciclo de urea.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150238P | 2015-04-20 | 2015-04-20 | |
| US201562150676P | 2015-04-21 | 2015-04-21 | |
| US201562211619P | 2015-08-28 | 2015-08-28 | |
| US201562255300P | 2015-11-13 | 2015-11-13 | |
| US201662276754P | 2016-01-08 | 2016-01-08 | |
| PCT/US2016/028298 WO2016172112A1 (en) | 2015-04-20 | 2016-04-19 | Formulations of l-ornithine phenylacetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013170A true MX2017013170A (es) | 2018-04-11 |
Family
ID=57144228
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013170A MX2017013170A (es) | 2015-04-20 | 2016-04-19 | Formulaciones de fenilacetato de l-ornitina. |
| MX2022003855A MX2022003855A (es) | 2015-04-20 | 2017-10-12 | Formulaciones de fenilacetato de l-ornitina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003855A MX2022003855A (es) | 2015-04-20 | 2017-10-12 | Formulaciones de fenilacetato de l-ornitina. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160338982A1 (es) |
| EP (2) | EP3285756B1 (es) |
| JP (2) | JP2018513171A (es) |
| KR (1) | KR20180006904A (es) |
| CN (2) | CN107708684A (es) |
| AU (2) | AU2016252382A1 (es) |
| CA (1) | CA2983146C (es) |
| DK (1) | DK3285756T3 (es) |
| ES (1) | ES2944311T3 (es) |
| HK (1) | HK1251149A1 (es) |
| MX (2) | MX2017013170A (es) |
| RU (1) | RU2755904C2 (es) |
| WO (1) | WO2016172112A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537974T3 (es) | 2004-11-26 | 2015-06-16 | Ucl Business Plc | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática |
| SG174982A1 (en) | 2009-04-03 | 2011-11-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| ES2517340T3 (es) | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
| KR20230018526A (ko) | 2014-11-24 | 2023-02-07 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
| CA2995823A1 (en) | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| US11219611B2 (en) | 2015-11-13 | 2022-01-11 | Ocera Therapeutics, Inc. | Formulations of L-ornithine phenylacetate |
| WO2017083758A1 (en) * | 2015-11-13 | 2017-05-18 | Ocera Therapeutics, Inc. | Formulation of l-ornithine phenylacetate |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| KR20200024145A (ko) | 2017-05-11 | 2020-03-06 | 오세라 테라퓨틱스, 아이엔씨. | L-오르니틴 페닐아세테이트의 제조방법 |
| CN111295187A (zh) | 2017-08-14 | 2020-06-16 | 胺细拉健康公司 | 用于治疗肝脏疾病的氨基酸组合物 |
| EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| IL116674A (en) * | 1995-01-09 | 2003-05-29 | Mendell Co Inc Edward | Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof |
| ES2537974T3 (es) | 2004-11-26 | 2015-06-16 | Ucl Business Plc | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática |
| AU2015221466B2 (en) * | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| SG174982A1 (en) * | 2009-04-03 | 2011-11-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| ES2517340T3 (es) * | 2009-06-08 | 2014-11-03 | Ucl Business Plc | Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato |
| AU2014250643B2 (en) * | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| WO2012048043A1 (en) | 2010-10-06 | 2012-04-12 | Ocera Therapeutics, Inc. | Methods of making l-ornithine phenyl acetate |
-
2016
- 2016-04-19 US US15/133,087 patent/US20160338982A1/en not_active Abandoned
- 2016-04-19 CA CA2983146A patent/CA2983146C/en active Active
- 2016-04-19 AU AU2016252382A patent/AU2016252382A1/en not_active Abandoned
- 2016-04-19 WO PCT/US2016/028298 patent/WO2016172112A1/en active Application Filing
- 2016-04-19 EP EP16783692.3A patent/EP3285756B1/en active Active
- 2016-04-19 MX MX2017013170A patent/MX2017013170A/es unknown
- 2016-04-19 CN CN201680036045.1A patent/CN107708684A/zh active Pending
- 2016-04-19 CN CN202110931620.7A patent/CN113599350A/zh active Pending
- 2016-04-19 JP JP2017554815A patent/JP2018513171A/ja active Pending
- 2016-04-19 RU RU2017137643A patent/RU2755904C2/ru active
- 2016-04-19 EP EP23157390.8A patent/EP4205735A1/en not_active Withdrawn
- 2016-04-19 ES ES16783692T patent/ES2944311T3/es active Active
- 2016-04-19 KR KR1020177032260A patent/KR20180006904A/ko not_active Application Discontinuation
- 2016-04-19 DK DK16783692.3T patent/DK3285756T3/da active
-
2017
- 2017-10-12 MX MX2022003855A patent/MX2022003855A/es unknown
-
2018
- 2018-08-16 HK HK18110518.2A patent/HK1251149A1/zh unknown
-
2021
- 2021-02-05 AU AU2021200740A patent/AU2021200740A1/en active Pending
- 2021-12-22 US US17/559,453 patent/US20220184014A1/en not_active Abandoned
-
2022
- 2022-03-23 JP JP2022046762A patent/JP2022101549A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022003855A (es) | 2023-03-02 |
| CA2983146C (en) | 2023-09-12 |
| RU2017137643A3 (es) | 2019-09-17 |
| AU2016252382A1 (en) | 2017-11-02 |
| HK1251149A1 (zh) | 2019-01-25 |
| EP3285756B1 (en) | 2023-02-22 |
| WO2016172112A1 (en) | 2016-10-27 |
| DK3285756T3 (da) | 2023-05-08 |
| CA2983146A1 (en) | 2016-10-27 |
| EP3285756A4 (en) | 2019-01-23 |
| JP2018513171A (ja) | 2018-05-24 |
| AU2021200740A1 (en) | 2021-03-04 |
| US20220184014A1 (en) | 2022-06-16 |
| CN107708684A (zh) | 2018-02-16 |
| EP3285756A1 (en) | 2018-02-28 |
| JP2022101549A (ja) | 2022-07-06 |
| RU2017137643A (ru) | 2019-05-20 |
| EP4205735A1 (en) | 2023-07-05 |
| CN113599350A (zh) | 2021-11-05 |
| US20160338982A1 (en) | 2016-11-24 |
| RU2755904C2 (ru) | 2021-09-22 |
| KR20180006904A (ko) | 2018-01-19 |
| ES2944311T3 (es) | 2023-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003855A (es) | Formulaciones de fenilacetato de l-ornitina. | |
| MX2022001517A (es) | Formulaciones de fenilacetato de l-ornitina. | |
| CY1123845T1 (el) | Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων | |
| HRP20210212T1 (hr) | Triciklični spoj kao antikancerogeni agensi | |
| MA42950A (fr) | Administration d'agents de potentialisation de cftr modifiés au deutérium | |
| PH12014502603A1 (en) | D-amino acid compounds for liver disease | |
| MX2012011222A (es) | Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales. | |
| PH12015502588A1 (en) | 4`-fluoro-2`-methyl substituted nucleoside derivatives | |
| MX2015014816A (es) | Compuestos de microarn y metodos para modular al mir-122. | |
| PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| UY36586A (es) | Heterociclilmetiltienouracilos y uso de los mismos | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| UA116053C2 (uk) | Застосування похідних бензоімідазолу-проліну | |
| BR112018000217A2 (pt) | sistemas de distribuição de nanopartículas aperfeiçoados | |
| MX2018007871A (es) | Composiciones para el cuidado personal. | |
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| MX2015014307A (es) | Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados. | |
| EA201890477A1 (ru) | Инкапсулированная композиция финголимода | |
| PH12018500895A1 (en) | Formulation of l-ornithine phenylacetate | |
| BR112017006449A2 (pt) | concentrado alimentar gelificado, processo de preparo e uso do mesmo | |
| MX2022004449A (es) | Dosis y usos de fenilacetato de ornitina para el tratamiento de hiperamonemia. | |
| BR112018004244A2 (pt) | formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso | |
| CL2020001559A1 (es) | Derivados glucosídicos de treprostinilo. | |
| BR112017006438A2 (pt) | concentrado alimentar gelificado, processo para a preparação e uso do mesmo | |
| MX2021001361A (es) | Composicion liquida de fibrinogeno humano. |